O	0	8	Efficacy
O	9	12	and
O	13	19	safety
O	20	22	of
B-intervention	23	25	CT
I-intervention	25	26	-
I-intervention	26	28	P6
O	29	35	versus
B-control	36	45	reference
I-control	46	57	trastuzumab
O	58	60	in
B-eligibility	61	65	HER2
I-eligibility	65	66	-
I-eligibility	66	74	positive
I-eligibility	75	80	early
I-eligibility	81	87	breast
I-eligibility	88	94	cancer
O	94	95	:
O	96	103	updated
O	104	111	results
O	112	114	of
O	115	116	a
O	117	127	randomised
O	128	133	phase
O	134	135	3
O	136	141	trial
O	141	142	.

O	143	154	Neoadjuvant
O	155	157	CT
O	157	158	-
O	158	160	P6
O	160	161	,
O	162	163	a
O	164	175	trastuzumab
O	176	186	biosimilar
O	186	187	,
O	188	200	demonstrated
O	201	211	equivalent
O	212	220	efficacy
O	221	223	to
O	224	233	reference
O	234	245	trastuzumab
O	246	248	in
O	249	250	a
O	251	256	phase
O	257	258	3
O	259	264	trial
O	265	267	of
O	268	272	HER2
O	272	273	-
O	273	281	positive
O	282	287	early
O	287	288	-
O	288	293	stage
O	294	300	breast
O	301	307	cancer
O	308	309	(
O	309	312	EBC
O	312	313	)
O	314	315	(
O	315	326	NCT02162667
O	326	327	)
O	327	328	.

O	329	331	We
O	332	338	report
O	339	343	post
O	344	347	hoc
O	348	356	analyses
O	357	367	evaluating
O	368	380	pathological
O	381	389	complete
O	390	398	response
O	399	400	(
O	400	403	pCR
O	403	404	)
O	405	408	and
O	409	415	breast
O	416	419	pCR
O	420	429	alongside
O	430	440	additional
O	441	449	efficacy
O	450	453	and
O	454	460	safety
O	461	469	measures
O	469	470	.

O	471	480	Following
O	481	492	neoadjuvant
O	493	502	treatment
O	503	506	and
O	507	514	surgery
O	514	515	,
O	516	524	patients
O	525	533	received
O	534	542	adjuvant
O	543	545	CT
O	545	546	-
O	546	548	P6
O	549	551	or
O	552	563	trastuzumab
O	564	565	(
O	565	566	6
O	567	569	mg
O	569	570	/
O	570	572	kg
O	572	573	)
O	574	579	every
O	580	581	3
O	582	587	weeks
O	588	591	for
O	592	593	â‰¤
O	594	595	1
O	596	600	year
O	600	601	.

O	602	604	In
O	605	610	total
O	610	611	,
B-intervention-participants	612	615	271
O	616	619	and
B-control-participants	620	623	278
O	624	632	patients
O	633	641	received
O	642	644	CT
O	644	645	-
O	645	647	P6
O	648	651	and
O	652	663	trastuzumab
O	663	664	,
O	665	677	respectively
O	677	678	.

B-outcome	679	682	pCR
O	683	686	and
B-outcome	687	693	breast
I-outcome	694	697	pCR
I-outcome	698	703	rates
O	704	708	were
O	709	719	comparable
O	720	727	between
O	728	737	treatment
O	738	744	groups
O	745	755	regardless
O	756	758	of
O	759	762	age
O	762	763	,
O	764	770	region
O	770	771	,
O	772	774	or
O	775	783	clinical
O	784	789	stage
O	789	790	.

O	791	798	Overall
O	798	799	,
B-iv-bin-percent	800	802	47
I-iv-bin-percent	802	803	.
I-iv-bin-percent	803	804	6
I-iv-bin-percent	804	805	%
O	806	807	(
O	807	809	CT
O	809	810	-
O	810	812	P6
O	812	813	)
O	814	817	and
B-cv-bin-percent	818	820	52
I-cv-bin-percent	820	821	.
I-cv-bin-percent	821	822	2
I-cv-bin-percent	822	823	%
O	824	825	(
O	825	836	trastuzumab
O	836	837	)
O	838	840	of
O	841	849	patients
O	850	861	experienced
B-outcome	862	867	study
I-outcome	868	872	drug
I-outcome	872	873	-
I-outcome	873	880	related
I-outcome	881	890	treatment
I-outcome	890	891	-
I-outcome	891	899	emergent
I-outcome	900	907	adverse
I-outcome	908	914	events
O	915	916	(
O	916	921	TEAEs
O	921	922	)
O	922	923	,
O	924	933	including
O	934	936	17
O	937	945	patients
O	946	955	reporting
B-outcome	956	961	heart
I-outcome	962	969	failure
O	970	971	(
O	971	973	CT
O	973	974	-
O	974	976	P6
O	976	977	:
B-iv-bin-abs	978	980	10
O	980	981	;
O	982	993	trastuzumab
O	993	994	:
B-cv-bin-abs	995	996	7
O	996	997	)
O	997	998	.

B-iv-bin-abs	999	1002	Two
O	1003	1005	CT
O	1005	1006	-
O	1006	1008	P6
O	1009	1012	and
B-cv-bin-abs	1013	1018	three
O	1019	1030	trastuzumab
O	1031	1039	patients
B-outcome	1040	1052	discontinued
I-outcome	1053	1061	adjuvant
I-outcome	1062	1071	treatment
O	1072	1075	due
O	1076	1078	to
O	1079	1084	TEAEs
O	1084	1085	.

O	1086	1094	Adjuvant
O	1095	1097	CT
O	1097	1098	-
O	1098	1100	P6
O	1101	1113	demonstrated
O	1114	1124	comparable
O	1125	1133	efficacy
O	1134	1137	and
O	1138	1144	safety
O	1145	1147	to
O	1148	1159	trastuzumab
O	1160	1162	at
O	1163	1164	1
O	1165	1169	year
O	1170	1172	in
O	1173	1181	patients
O	1182	1186	with
O	1187	1191	HER2
O	1191	1192	-
O	1192	1200	positive
O	1201	1204	EBC
O	1204	1205	,
O	1206	1216	supporting
O	1217	1219	CT
O	1219	1220	-
O	1220	1222	P6
O	1223	1226	and
O	1227	1238	trastuzumab
O	1239	1252	comparability
O	1252	1253	.
